友芝友生物-B(02496)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

02496 友芝友生物-B

交易中 11-19 11:25:56

4.700

-0.180

-3.69%

最高4.700	最低4.700	成交量400.00
今开4.700	昨收4.880	日振幅0.00%
总市值5.24亿	流通市值5.24亿	总股本1.11亿
成交额1,880	换手率0.00%	流通股本1.11亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"02496","market":"HK","secType":"STK","nameCN":"友芝友生物-B","latestPrice":4.7,"timestamp":1731979802715,"preClose":4.88,"halted":0,"volume":400,"delay":0,"floatShares":111468814,"shares":111468814,"eps":-1.1143695,"marketStatus":"交易中","marketStatusCode":2,"change":-0.18,"latestTime":"11-19 11:25:56","open":4.7,"high":4.7,"low":4.7,"amount":1880,"amplitude":0,"askPrice":4.7,"askSize":800,"bidPrice":0,"bidSize":0,"shortable":0,"etf":0,"ttmEps":-1.0337788978295888,"exchange":"SEHK","tradingStatus":2,"nextMarketStatus":{"tag":"午间休市","tradingStatus":4,"beginTime":1731988800000},"adr":0,"listingDate":1695571200000,"adjPreClose":4.88,"openAndCloseTimeList":[[1731979800000,1731988800000],[1731992400000,1732003200000]],"volumeRatio":0.270936,"lotSize":200,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/02496/tweets","defaultTab":"tweets","newsList":[{"id":"2482231787","title":"友芝友生物-B盘中异动 股价大跌6.93%","url":"https://stock-news.laohu8.com/highlight/detail?id=2482231787","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2482231787?lang=zh_cn&edition=full","pubTime":"2024-11-12 15:19","pubTimestamp":1731395961,"startTime":"0","endTime":"0","summary":"2024年11月12日下午盘15时19分，友芝友生物-B股票出现异动，股价大幅下挫6.93%。截至发稿，该股报5.100港元/股，成交量2.04万股，换手率0.02%，振幅0.00%。友芝友生物-B股票所在的生物技术行业中，整体跌幅为1.25%。其相关个股中，宜明昂科-B、东曜药业-B、奥星生命科技涨幅较大，振幅较大的相关个股有晶泰科技、宜明昂科-B、绿竹生物-B，振幅分别为23.29%、23.13%、18.42%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024111215192198e42048&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024111215192198e42048&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1161","02496"],"gpt_icon":0},{"id":"2481199721","title":"友芝友生物-B盘中异动 临近午盘急速下挫5.01%","url":"https://stock-news.laohu8.com/highlight/detail?id=2481199721","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2481199721?lang=zh_cn&edition=full","pubTime":"2024-11-08 11:39","pubTimestamp":1731037156,"startTime":"0","endTime":"0","summary":"2024年11月08日临近午盘11时39分，友芝友生物-B股票出现异动，股价急速下跌5.01%。截至发稿，该股报5.500港元/股，成交量400股，换手率0.00%，振幅0.00%。机构评级方面，目前暂无机构对该股做出“买入、持有、卖出”建议。友芝友生物-B股票所在的生物技术行业中，整体涨幅为0.14%。其相关个股中，科济药业-B、帝王国际投资、中生北控生物科技涨幅较大，振幅较大的相关个股有科济药业-B、帝王国际投资、康宁杰瑞制药-B，振幅分别为34.87%、29.82%、19.64%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241108113916971a5453&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241108113916971a5453&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1161","02496"],"gpt_icon":0},{"id":"2477388437","title":"友芝友生物-B(02496)委任温植成为非执行董事","url":"https://stock-news.laohu8.com/highlight/detail?id=2477388437","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2477388437?lang=zh_cn&edition=full","pubTime":"2024-10-22 17:36","pubTimestamp":1729589813,"startTime":"0","endTime":"0","summary":"智通财经APP讯，友芝友生物-B(02496)公布，由于上述第1项至第2项决议案于临时股东大会上获股东正式通过成为普通决议案，故郭宏伟已被罢免非执行董事一职，而温植成已获委任为非执行董事，均自临时股东大会结束时生效。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1197460.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["02496","BK1161"],"gpt_icon":0},{"id":"2475625860","title":"友芝友生物-B盘中异动 早盘股价大跌9.09%","url":"https://stock-news.laohu8.com/highlight/detail?id=2475625860","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2475625860?lang=zh_cn&edition=full","pubTime":"2024-10-16 09:39","pubTimestamp":1729042799,"startTime":"0","endTime":"0","summary":"2024年10月16日早盘09时39分，友芝友生物-B股票出现波动，股价急速下挫9.09%。截至发稿，该股报6.300港元/股，成交量600股，换手率0.00%，振幅0.14%。机构评级方面，目前暂无机构对该股做出“买入、持有、卖出”建议。友芝友生物-B股票所在的生物技术行业中，整体跌幅为0.59%。其相关个股中，宜明昂科-B、再鼎医药、迈博药业-B涨幅较大，振幅较大的相关个股有科笛-B、康诺亚-B、宜明昂科-B，振幅分别为8.50%、7.02%、6.08%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241016093959a1e0f691&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241016093959a1e0f691&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["02496","BK1161"],"gpt_icon":0},{"id":"2473732446","title":"总金额或超10亿元，中国生物制药获一款双抗独家许可","url":"https://stock-news.laohu8.com/highlight/detail?id=2473732446","media":"中新经纬","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2473732446?lang=zh_cn&edition=full","pubTime":"2024-10-08 15:57","pubTimestamp":1728374260,"startTime":"0","endTime":"0","summary":"销售峰值预计20亿元对于本次与友芝友生物达成合作的原因，中国生物制药在公告中表示，肿瘤领域是该集团创新研发的四大重点治疗领域之一，也是最重要的收入来源。2023年以来，中国生物制药已与普莱医药、鸿运华宁、益方生物、勃林格殷格翰等创新药企达成合作协议。2024年4月，中国生物制药发布公告称与勃林格殷格翰签署战略合作协议，双方将依托各自优势和资源，共同研发并在中国商业化勃林格殷格翰的肿瘤药物管线。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202410081729279597ec2d&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202410081729279597ec2d&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1161","01177","BK1191","BK1589","02496","BK1521","BK1515"],"gpt_icon":0},{"id":"2473452299","title":"友芝友生物-B：与正大天晴达成3.15亿元合作，M701临床III期进展顺利","url":"https://stock-news.laohu8.com/highlight/detail?id=2473452299","media":"和讯网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2473452299?lang=zh_cn&edition=full","pubTime":"2024-10-08 08:57","pubTimestamp":1728349065,"startTime":"0","endTime":"0","summary":"根据协议，友芝友生物将授予正大天晴在特定地区和领域内对许可产品进行开发、注册、生产和商业化的独家权利。正大天晴将根据研发进展向友芝友生物支付最高达人民币3.15亿元的首付款及额外开发里程碑付款。友芝友生物自主研发的生物一类新药M701，目前处于临床试验III期，是国内首个自主开发并进入临床试验阶段的CD3/EpCAM双特异性抗体。此外，M701正在进行一项针对非小细胞肺癌引发的恶性胸水的II期临床试验。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202410080910429596bb5f&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202410080910429596bb5f&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["02496","BK1161"],"gpt_icon":0},{"id":"2473451195","title":"友芝友生物(02496.HK)授予中生制药(01177.HK)附属正大天晴M701产品独家许可权","url":"https://stock-news.laohu8.com/highlight/detail?id=2473451195","media":"阿斯达克财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2473451195?lang=zh_cn&edition=full","pubTime":"2024-10-08 08:40","pubTimestamp":1728348000,"startTime":"0","endTime":"0","summary":"友芝友生物公布，授予中国生物制药附属正大天晴在内地及人类疾病防治的全领域内，对任何含有M701的产品及其稳定剂进行开发、注册、生产及商业化的独家、可分许可的许可。根据研发进展情况，正大天晴将就许可产品向公司支付最高合共3.15亿元人民币(下同)的首付款及额外开发里程碑付款。基于许可产品年度销售净额达到的水平，正大天晴应支付各种指定的销售里程碑付款。正大天晴应付公司的最高销售里程碑付款合共为7亿元。","market":"other","thumbnail":"https://plib.aastocks.com/aafnnews/image/medialib/20230918101532905_s.jpg","type":0,"news_type":0,"thumbnails":["https://plib.aastocks.com/aafnnews/image/medialib/20230918101532905_s.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1386565/latest-news/AAFN","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks_highlight","symbols":["BK1161","BK1191","02496","BK1515","BK1574","BK1521","BK1589","01477","01177"],"gpt_icon":0},{"id":"2473456732","title":"友芝友生物-B(02496)与正大天晴就双特异性抗体M701订立许可与合作协议","url":"https://stock-news.laohu8.com/highlight/detail?id=2473456732","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2473456732?lang=zh_cn&edition=full","pubTime":"2024-10-08 08:05","pubTimestamp":1728345935,"startTime":"0","endTime":"0","summary":"根据研发进展情况，正大天晴将就许可产品向公司支付最高合共人民币3.15亿元的首付款及额外开发里程碑付款。据悉，双特异性抗体M701是公司自主研发的生物一类新药，拟被开发用于肿瘤引起的恶性胸水和恶性腹水的治疗，目前处于临床试验III期，是国内首个自主开发并进入临床试验阶段的CD3/EpCAM双特异性抗体。此外，M701正在进行一项针对非小细胞肺癌引发的恶性胸水的II期临床试验。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1190728.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","02496"],"gpt_icon":0},{"id":"2473543727","title":"中国生物制药：与友芝友生物签署独家许可与合作协议","url":"https://stock-news.laohu8.com/highlight/detail?id=2473543727","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2473543727?lang=zh_cn&edition=full","pubTime":"2024-10-08 06:20","pubTimestamp":1728339654,"startTime":"0","endTime":"0","summary":"格隆汇10月8日丨中国生物制药(01177.HK)发布公告，公司附属公司正大天晴药业集团股份有限公司(“正大天晴”)与武汉友芝友生物制药股份有限公司(“友芝友生物”)签署独家许可与合作协议，据此，正大天晴获得友芝友生物研发的M701在中国大陆地区的开发、注册、生产和商业化的独家、可分许可的许可。正大天晴将根据研发进展情况，就许可产品向友芝友生物支付约3.15亿元人民币的首付款及研发里程碑款项，并支付最高不超过7亿元人民币的销售里程碑款项，同时按年净销售额的个位数至低双位数百分比向友芝友生物支付分层特权使用费。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241008062054ab682915&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241008062054ab682915&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["01177","BK1161","BK1515","02496","BK1521","BK1589","BK1191"],"gpt_icon":0},{"id":"2472935987","title":"友芝友生物-B盘中异动 临近收盘快速上涨5.04%报7.300港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2472935987","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2472935987?lang=zh_cn&edition=full","pubTime":"2024-10-04 15:45","pubTimestamp":1728027931,"startTime":"0","endTime":"0","summary":"2024年10月04日临近收盘15时45分，友芝友生物-B股票出现异动，股价快速拉升5.04%。截至发稿，该股报7.300港元/股，成交量1200股，换手率0.00%，振幅0.00%。资金方面，该股资金流入0港元，流出6950港元。友芝友生物-B股票所在的生物技术行业中，整体涨幅为4.89%。其相关个股中，创胜集团-B、复旦张江、君实生物涨幅较大，振幅较大的相关个股有正大企业国际、创胜集团-B、复旦张江，振幅分别为49.65%、44.35%、32.82%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024100415453198e3a910&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024100415453198e3a910&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1161","02496"],"gpt_icon":0},{"id":"2471870657","title":"友芝友生物-B(02496)提名温植成为第一届董事会非执行董事","url":"https://stock-news.laohu8.com/highlight/detail?id=2471870657","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2471870657?lang=zh_cn&edition=full","pubTime":"2024-09-30 18:34","pubTimestamp":1727692477,"startTime":"0","endTime":"0","summary":"董事会谨此宣布，于2024年9月30日，董事会决议罢免郭宏伟的非执行董事职务，惟须待公司股东批准后方可作实。董事会已提名温植成为第一届董事会非执行董事，任期自公司临时股东大会批准日期起至第一届董事会任期届满时为止。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1189134.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["02496","BK1161"],"gpt_icon":0},{"id":"2471482570","title":"友芝友生物-B盘中异动 下午盘股价大涨11.49%","url":"https://stock-news.laohu8.com/highlight/detail?id=2471482570","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2471482570?lang=zh_cn&edition=full","pubTime":"2024-09-30 14:41","pubTimestamp":1727678497,"startTime":"0","endTime":"0","summary":"2024年09月30日下午盘14时41分，友芝友生物-B股票出现异动，股价快速上涨11.49%。截至发稿，该股报6.600港元/股，成交量9400股，换手率0.01%，振幅18.41%。资金方面，该股资金流入4.4268万港元，流出4898港元。机构评级方面，目前暂无机构对该股做出“买入、持有、卖出”建议。友芝友生物-B股票所在的生物技术行业中，整体涨幅为3.24%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202409301441379719d85b&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202409301441379719d85b&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1161","02496"],"gpt_icon":0},{"id":"2469311222","title":"友芝友生物(02496.HK)M701恶性胸水Ib期中期研究结果良好","url":"https://stock-news.laohu8.com/highlight/detail?id=2469311222","media":"阿斯达克财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2469311222?lang=zh_cn&edition=full","pubTime":"2024-09-23 21:52","pubTimestamp":1727099520,"startTime":"0","endTime":"0","summary":"友芝友生物－Ｂ(02496.HK) 公布，公司自主研发的上皮细胞黏附分子“EpCAM”和分化簇3“CD3”双靶向的在研双特异性抗体药物M701在内地开展的治疗晚期非小细胞肺癌引发的恶性胸水的Ib期临床研的中期分析数据已以壁报讨论形式在2024年欧洲肿瘤内科学会(ESMO)年会上公布，M701安全性结果良好，以及展示了良好的胸水控制效果。基于良好的安全性和疗效结果，公司正在积极推进恶性胸水的II期临床研究。(de/d)(港股报价延迟最少十五分钟。)AASTOCKS新闻","market":"fut","thumbnail":"https://plib.aastocks.com/aafnnews/image/medialib/20220210100852532_s.jpg","type":0,"news_type":0,"thumbnails":["https://plib.aastocks.com/aafnnews/image/medialib/20220210100852532_s.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1383180/latest-news/AAFN","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks_highlight","symbols":["BK1161","02496"],"gpt_icon":0},{"id":"2469191009","title":"友芝友生物-B(02496)：M701恶性胸水Ib期中期研究数据在2024年ESMO会议上公布","url":"https://stock-news.laohu8.com/highlight/detail?id=2469191009","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2469191009?lang=zh_cn&edition=full","pubTime":"2024-09-23 18:54","pubTimestamp":1727088855,"startTime":"0","endTime":"0","summary":"智通财经APP讯，友芝友生物-B 发布公告，公司自主研发的上皮细胞黏附分子和分化簇3双靶向的在研双特异性抗体药物 M701在中国开展的治疗晚期非小细胞肺癌引发的恶性胸水的Ib期临床研究的中期分析数据已以壁报讨论形式在2024年欧洲肿瘤内科学会年会上公布。M701胸腔灌注安全性评估良好。胸水中肿瘤细胞检测结果也提示，在胸部灌注M701 3次以后，EpCAM阳性肿瘤细胞较基线出现了显著性的下降。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1186009.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["02496","BK1161"],"gpt_icon":0},{"id":"2463255964","title":"《业绩》友芝友生物(02496.HK)中期亏损收窄至7,840万人民币","url":"https://stock-news.laohu8.com/highlight/detail?id=2463255964","media":"阿斯达克财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2463255964?lang=zh_cn&edition=full","pubTime":"2024-08-29 21:08","pubTimestamp":1724936880,"startTime":"0","endTime":"0","summary":"友芝友生物－Ｂ(02496.HK) 公布6月止六个月中期业绩，其他收入录得479万人民币(下同)，按年下降30.8%。亏损由上年同期8,657万元，收窄至7,840万元，每股亏损40分。不派中期息。(de/d)(港股报价延迟最少十五分钟。)过往派息公布日期派息事项派息内容2024/03/28末期业绩无派息AASTOCKS新闻","market":"fut","thumbnail":"https://plib.aastocks.com/aafnnews/image/medialib/20230913084201322_s.jpg","type":0,"news_type":0,"thumbnails":["https://plib.aastocks.com/aafnnews/image/medialib/20230913084201322_s.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1377170/latest-news/AAFN","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks_highlight","symbols":["BK1161","02496"],"gpt_icon":0},{"id":"2463231993","title":"友芝友生物-B(02496)发布中期业绩，净亏损7839.6万元 同比收窄9.44%","url":"https://stock-news.laohu8.com/highlight/detail?id=2463231993","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2463231993?lang=zh_cn&edition=full","pubTime":"2024-08-29 19:36","pubTimestamp":1724931366,"startTime":"0","endTime":"0","summary":"智通财经APP讯，友芝友生物-B 发布截至2024年6月30日止6个月中期业绩，该集团取得其他收入人民币478.6万元，同比减少30.83%;研发开支7029万元，同比减少1.83%;期内亏损7839.6万元，同比减少9.44%;每股亏损0.4元。公司开发M701主要是用于治疗MA及MPE。一旦M701获得商业化的批准，公司的内部商业化团队将首先专注于M701的市场推广和销售。公司还计划进一步扩大公司的销售队伍，以配合未来M701的销售需求。公司计划于2024年下半年开展合同销售组织订约协商。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1175210.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","02496"],"gpt_icon":0},{"id":"2463248239","title":"友芝友生物-B(02496)：陈斌获委任为提名委员会成员","url":"https://stock-news.laohu8.com/highlight/detail?id=2463248239","media":"智通财经网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2463248239?lang=zh_cn&edition=full","pubTime":"2024-08-29 19:24","pubTimestamp":1724930684,"startTime":"0","endTime":"0","summary":"友芝友生物-B(02496)发布公告，独立非执行董事陈斌博士获委任为提名委员会成员...","market":"hk","thumbnail":"https://img.zhitongcaijing.com/gonggao/ztcj_announce_24.jpeg?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250","type":0,"news_type":0,"thumbnails":["https://img.zhitongcaijing.com/gonggao/ztcj_announce_24.jpeg?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1175180.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["BK1161","02496"],"gpt_icon":0},{"id":"2462738271","title":"友芝友生物(02496.HK)：非执董郭宏伟正接受内地纪律审查及监察调查","url":"https://stock-news.laohu8.com/highlight/detail?id=2462738271","media":"阿斯达克财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2462738271?lang=zh_cn&edition=full","pubTime":"2024-08-28 09:12","pubTimestamp":1724807520,"startTime":"0","endTime":"0","summary":"友芝友生物-B(02496.HK) 公布，注意到交通银行天津市分行原党委书记、行长郭宏伟涉嫌严重违纪违法，目前正接受纪律审查和监察调查。友芝友生物-B表示，郭宏伟除担任公司非执行董事外，未担任其他任何职务，且不参与公司的日常经营管理。因此，上述事项预计不会对友芝友生物日常经营管理产生任何重大不利影响。(js/a)(港股报价延迟最少十五分钟。)AASTOCKS新闻","market":"sh","thumbnail":"https://plib.aastocks.com/aafnnews/image/medialib/20230918101532905_s.jpg","type":0,"news_type":0,"thumbnails":["https://plib.aastocks.com/aafnnews/image/medialib/20230918101532905_s.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/analysis/china-hot-topic-content.aspx?id=NOW.1375991&catg=4&source=AAFN","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks_highlight","symbols":["02496","BK1161"],"gpt_icon":0},{"id":"2462215207","title":"友芝友生物-B(02496)：郭宏伟涉嫌严重违纪违法，目前正接受纪律审查和监察调查","url":"https://stock-news.laohu8.com/highlight/detail?id=2462215207","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2462215207?lang=zh_cn&edition=full","pubTime":"2024-08-27 18:25","pubTimestamp":1724754354,"startTime":"0","endTime":"0","summary":"智通财经APP讯，友芝友生物-B 发布公告，公司董事会注意到根据中共中央纪律检查委员会及中华人民共和国国家监察委员会官方网站近日讯息，据中央纪委国家监委驻交通银行纪检监察组、天津市纪委监委消息：交通银行天津市分行原党委书记、行长郭宏伟涉嫌严重违纪违法，目前正接受纪律审查和监察调查。郭博士除担任公司非执行董事外，未担任公司其他任何职务，不参与公司日常经营管理。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1171933.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","02496"],"gpt_icon":0},{"id":"2461339561","title":"友芝友生物－Ｂ(02496)股价下跌8.023%，现价港币$6.42","url":"https://stock-news.laohu8.com/highlight/detail?id=2461339561","media":"阿斯达克财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2461339561?lang=zh_cn&edition=full","pubTime":"2024-08-22 10:45","pubTimestamp":1724294700,"startTime":"0","endTime":"0","summary":"[下跌股]友芝友生物－Ｂ(02496) 股价在上午10:45比前收市价下跌8.023%，现股价为港币$6.42。至目前为止，今日最高价为$6.42，而最低价为$6.42。总成交量为400股，总成交金额为港币$2568。","market":"other","thumbnail":"https://plib.aastocks.com/aafnnews/image/medialib/20180205152747204_s.jpg","type":0,"news_type":0,"thumbnails":["https://plib.aastocks.com/aafnnews/image/medialib/20180205152747204_s.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aamm-content/AAD240822793/aamm-all-category","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks_highlight","symbols":["02496","BK1161"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.yzybio.com","stockEarnings":[{"period":"1week","weight":-0.1095},{"period":"1month","weight":-0.2116},{"period":"3month","weight":-0.3029},{"period":"6month","weight":-0.345},{"period":"1year","weight":-0.459},{"period":"ytd","weight":-0.4517}],"compareEarnings":[{"period":"1week","weight":-0.0416},{"period":"1month","weight":-0.059},{"period":"3month","weight":0.118},{"period":"6month","weight":0.0198},{"period":"1year","weight":0.1216},{"period":"ytd","weight":0.1484}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"武汉友芝友生物制药股份有限公司是一家主要从事药品研发、生产和销售的中国公司。该公司主要从事双特异性抗体药物的研发及产业化。该公司主要产品包括抗程序性死亡受体1和抗分化簇3、抗分化簇19和抗分化簇3、抗CDX和分化簇3。该公司的药品主要应用于肿瘤、免疫、炎症、心血管、感染等重大疾病领域。","exchange":"SEHK","name":"友芝友生物-B","nameEN":"YZYBIO-B"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.29.1","shortVersion":"4.29.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"友芝友生物-B(02496)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供友芝友生物-B(02496)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"友芝友生物-B,02496,友芝友生物-B股票,友芝友生物-B股票老虎,友芝友生物-B股票老虎国际,友芝友生物-B行情,友芝友生物-B股票行情,友芝友生物-B股价,友芝友生物-B股市,友芝友生物-B股票价格,友芝友生物-B股票交易,友芝友生物-B股票购买,友芝友生物-B股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"友芝友生物-B(02496)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供友芝友生物-B(02496)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}